Both of these biotech stocks have tremendous momentum. Which is more likely to deliver bigger returns in the future?
News & Analysis: Cara Therapeutics
This small biotech expects to announce results from two clinical studies in 2019.
These three biotech stocks are worth buying this month.
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
The pharma company announced full-year 2018 operating results and reiterated the road map for the year ahead.
CARA earnings call for the period ending December 31, 2018.
Which stock wins in a matchup between an up-and-coming biotech and a top supplier to the cannabis industry?
An important phase 3 clinical trial enrolled its last patient at the beginning of the year, which means top-line results could be right around the corner.
Both of these biotech companies are getting close to achieving commercial successes.
The $600 million pharma company is working on a drug with estimated peak annual sales of $500 million.